Search

Your search keyword '"Griffioen, Arjan W."' showing total 1,033 results
Start Over Author "Griffioen, Arjan W."
1,033 results on '"Griffioen, Arjan W."'

3. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy

Author

Nowak-Sliwinska, Patrycja, van Beijnum, Judy R., Griffioen, Christian J., Huinen, Zowi R., Sopesens, Nadine Grima, Schulz, Ralph, Jenkins, Samir V., Dings, Ruud P. M., Groenendijk, Floris H., Huijbers, Elisabeth J. M., Thijssen, Victor L. J. L., Jonasch, Eric, Vyth-Dreese, Florry A., Jordanova, Ekaterina S., Bex, Axel, Bernards, René, de Gruijl, Tanja D., and Griffioen, Arjan W.

Published
2023
Full Text
View/download PDF

8. Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress

Author

Kahn, Susan R., Arnold, Donald M., Casari, Caterina, Desch, Karl C., Devreese, Katrien M.J., Favaloro, Emmanuel J., Gaertner, Florian, Gouw, Samantha C., Gresele, Paolo, Griffioen, Arjan W., Heger, Lukas, Kini, R. Manjunatha, Kohli, Shrey, Leader, Avi, Lisman, Ton, Lordkipanidzé, Marie, Mullins, Eric, Okoye, Helen Chioma, Rosovsky, Rachel P., Salles-Crawley, Isabelle I., Selby, Rita, Sholzberg, Michelle, Stegner, David, Violi, Francesco, Weyand, Angela C., Williams, Suzan, and Zheng, Ze

Published
2023
Full Text
View/download PDF

15. Nanoparticles Dysregulate the Human Placental Secretome with Consequences on Angiogenesis and Vascularization.

Author

Dugershaw‐Kurzer, Battuja, Bossart, Jonas, Buljan, Marija, Hannig, Yvette, Zehnder, Sarah, Gupta, Govind, Kissling, Vera M., Nowak‐Sliwinska, Patrycja, van Beijnum, Judy R., Griffioen, Arjan W., Masjosthusmann, Stefan, Zühr, Etta, Fritsche, Ellen, Hornung, René, Rduch, Thomas, and Buerki‐Thurnherr, Tina

Subjects
PLACENTA, NEOVASCULARIZATION, NANOPARTICLES, EXTRACELLULAR vesicles, TITANIUM dioxide
Abstract

Exposure to nanoparticles (NPs) in pregnancy is increasingly linked to adverse effects on embryo‐fetal development and health later in life. However, the developmental toxicity mechanisms of NPs are largely unknown, in particular potential effects on the placental secretome, which orchestrates many developmental processes pivotal for pregnancy success. This study demonstrates extensive material‐ and pregnancy stage‐specific deregulation of placental signaling from a single exposure of human placental explants to physiologically relevant concentrations of engineered (silica (SiO2) and titanium dioxide (TiO2) NPs) and environmental NPs (diesel exhaust particles, DEPs). This includes a multitude of secreted inflammatory, vascular, and endocrine placental factors as well as extracellular vesicle (EV)‐associated proteins. Moreover, conditioned media (CM) from NP‐exposed explants induce pronounced anti‐angiogenic and anti‐vasculogenic effects, while early neurodevelopmental processes are only marginally affected. These findings underscore the potential of metal oxide NPs and DEPs for widespread interference with the placental secretome and identify vascular morphogenesis as a sensitive outcome for the indirect developmental toxicity of different NPs. Overall, this work has profound implications for the future safety assessment of NPs for industrial, commercial, or medical applications in pregnancy, which should consider placenta‐mediated toxicity by holistic secretomics approaches to ensure the development of safe nanotechnologies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

Author

Smadja, David M., Mentzer, Steven J., Fontenay, Michaela, Laffan, Mike A., Ackermann, Maximilian, Helms, Julie, Jonigk, Danny, Chocron, Richard, Pier, Gerald B., Gendron, Nicolas, Pons, Stephanie, Diehl, Jean-Luc, Margadant, Coert, Guerin, Coralie, Huijbers, Elisabeth J. M., Philippe, Aurélien, Chapuis, Nicolas, Nowak-Sliwinska, Patrycja, Karagiannidis, Christian, Sanchez, Olivier, Kümpers, Philipp, Skurnik, David, Randi, Anna M., and Griffioen, Arjan W.

Published
2021
Full Text
View/download PDF

17. Consensus guidelines for the use and interpretation of angiogenesis assays

Author

Nowak-Sliwinska, Patrycja, Alitalo, Kari, Allen, Elizabeth, Anisimov, Andrey, Aplin, Alfred C, Auerbach, Robert, Augustin, Hellmut G, Bates, David O, van Beijnum, Judy R, Bender, R Hugh F, Bergers, Gabriele, Bikfalvi, Andreas, Bischoff, Joyce, Böck, Barbara C, Brooks, Peter C, Bussolino, Federico, Cakir, Bertan, Carmeliet, Peter, Castranova, Daniel, Cimpean, Anca M, Cleaver, Ondine, Coukos, George, Davis, George E, De Palma, Michele, Dimberg, Anna, Dings, Ruud PM, Djonov, Valentin, Dudley, Andrew C, Dufton, Neil P, Fendt, Sarah-Maria, Ferrara, Napoleone, Fruttiger, Marcus, Fukumura, Dai, Ghesquière, Bart, Gong, Yan, Griffin, Robert J, Harris, Adrian L, Hughes, Christopher CW, Hultgren, Nan W, Iruela-Arispe, M Luisa, Irving, Melita, Jain, Rakesh K, Kalluri, Raghu, Kalucka, Joanna, Kerbel, Robert S, Kitajewski, Jan, Klaassen, Ingeborg, Kleinmann, Hynda K, Koolwijk, Pieter, Kuczynski, Elisabeth, Kwak, Brenda R, Marien, Koen, Melero-Martin, Juan M, Munn, Lance L, Nicosia, Roberto F, Noel, Agnes, Nurro, Jussi, Olsson, Anna-Karin, Petrova, Tatiana V, Pietras, Kristian, Pili, Roberto, Pollard, Jeffrey W, Post, Mark J, Quax, Paul HA, Rabinovich, Gabriel A, Raica, Marius, Randi, Anna M, Ribatti, Domenico, Ruegg, Curzio, Schlingemann, Reinier O, Schulte-Merker, Stefan, Smith, Lois EH, Song, Jonathan W, Stacker, Steven A, Stalin, Jimmy, Stratman, Amber N, Van de Velde, Maureen, van Hinsbergh, Victor WM, Vermeulen, Peter B, Waltenberger, Johannes, Weinstein, Brant M, Xin, Hong, Yetkin-Arik, Bahar, Yla-Herttuala, Seppo, Yoder, Mervin C, and Griffioen, Arjan W

Subjects
Biochemistry and Cell Biology, Biological Sciences, Regenerative Medicine, Animals, Biological Assay, Guidelines as Topic, Humans, Mice, Neoplasms, Neovascularization, Pathologic, Angiogenesis, Aortic ring, Endothelial cell migration, Proliferation, Microfluidic, Zebrafish, Chorioallantoic membrane, Vascular network, Intussusceptive angiogenesis, Retinal vasculature, Corneal angiogenesis, Hindlimb ischemia, Myocardial angiogenesis, Recombinant proteins, Tip cells, Plug assay, Vessel co-option, Clinical Sciences, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Biochemistry and cell biology
Abstract

The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and future reference.

Published
2018

25. Optimization of drug combinations using Feedback System Control

Author

Nowak-Sliwinska, Patrycja, Weiss, Andrea, Ding, Xianting, Dyson, Paul J, van den Bergh, Hubert, Griffioen, Arjan W, and Ho, Chih-Ming

Subjects
Biomedical and Clinical Sciences, Medicinal and Biomolecular Chemistry, Chemical Sciences, Substance Misuse, Drug Abuse (NIDA only), Biological Assay, Drug Combinations, Drug Evaluation, Preclinical, Drug Synergism, Drug Therapy, Combination, Humans, Biological Sciences, Medical and Health Sciences, Bioinformatics
Abstract

We describe a protocol for the discovery of synergistic drug combinations for the treatment of disease. Synergistic drug combinations lead to the use of drugs at lower doses, which reduces side effects and can potentially lead to reduced drug resistance, while being clinically more effective than the individual drugs. To cope with the extremely large search space for these combinations, we developed an efficient combinatorial drug screening method called the Feedback System Control (FSC) technique. Starting with a broad selection of drugs, the method follows an iterative approach of experimental testing in a relevant bioassay and analysis of the results by FSC. First, the protocol uses a cell viability assay to generate broad dose-response curves to assess the efficacy of individual compounds. These curves are then used to guide the dosage input of each drug to be tested in combination. Data from applied drug combinations are input into the differential evolution (DE) algorithm, which predicts new combinations to be tested in vitro. This process identifies optimal drug-dose combinations, while saving orders of magnitude in experimental effort. The complete optimization process is estimated to take ∼4 weeks. FSC does not require insight into the disease mechanism, and it has therefore been applied to find combination therapies for many different pathologies, including cancer and infectious diseases, and it has also been used in organ transplantation.

Published
2016

28. A streamlined search technology for identification of synergistic drug combinations.

Author

Weiss, Andrea, Berndsen, Robert H, Ding, Xianting, Ho, Chih-Ming, Dyson, Paul J, van den Bergh, Hubert, Griffioen, Arjan W, and Nowak-Sliwinska, Patrycja

Subjects
Kidney, Cell Line, Tumor, Epithelial Cells, Humans, Benzamides, Imidazoles, Piperazines, Pyrazoles, Indazoles, Antineoplastic Agents, Drug Combinations, Drug Screening Assays, Antitumor, Cell Survival, Dose-Response Relationship, Drug, Drug Synergism, Dasatinib, Erlotinib Hydrochloride, Axitinib, Cell Line, Tumor, Drug Screening Assays, Antitumor, Dose-Response Relationship, Drug, Orphan Drug, Rare Diseases, Cancer, Kidney Disease, 5.1 Pharmaceuticals, Biochemistry and Cell Biology, Other Physical Sciences
Abstract

A major key to improvement of cancer therapy is the combination of drugs. Mixing drugs that already exist on the market may offer an attractive alternative. Here we report on a new model-based streamlined feedback system control (s-FSC) method, based on a design of experiment approach, for rapidly finding optimal drug mixtures with minimal experimental effort. We tested combinations in an in vitro assay for the viability of a renal cell adenocarcinoma (RCC) cell line, 786-O. An iterative cycle of in vitro testing and s-FSC analysis was repeated a few times until an optimal low dose combination was reached. Starting with ten drugs that target parallel pathways known to play a role in the development and progression of RCC, we identified the best overall drug combination, being a mixture of four drugs (axitinib, erlotinib, dasatinib and AZD4547) at low doses, inhibiting 90% of cell viability. The removal of AZD4547 from the optimized drug combination resulted in 80% of cell viability inhibition, while still maintaining the synergistic interaction. These optimized drug combinations were significantly more potent than monotherapies of all individual drugs (p

Published
2015

29. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Author

Weiss, Andrea, Ding, Xianting, van Beijnum, Judy R, Wong, Ieong, Wong, Tse J, Berndsen, Robert H, Dormond, Olivier, Dallinga, Marchien, Shen, Li, Schlingemann, Reinier O, Pili, Roberto, Ho, Chih-Ming, Dyson, Paul J, van den Bergh, Hubert, Griffioen, Arjan W, and Nowak-Sliwinska, Patrycja

Subjects
Biochemistry and Cell Biology, Biological Sciences, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Algorithms, Animals, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Cell Culture Techniques, Cell Line, Tumor, Cell Movement, Cell Survival, Chickens, Chorioallantoic Membrane, Cymenes, Drug Screening Assays, Antitumor, Endothelial Cells, Feedback, Female, Humans, Imidazoles, Mice, Mice, Nude, Neoplasm Transplantation, Neoplasms, Neovascularization, Pathologic, Organometallic Compounds, Ovarian Neoplasms, Platelet Endothelial Cell Adhesion Molecule-1, Quinolines, Stochastic Processes, Anti-angiogenesis, Combination therapy, Drug-drug interactions, Feedback system control, Search algorithm, Clinical Sciences, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Biochemistry and cell biology
Abstract

Drug combinations can improve angiostatic cancer treatment efficacy and enable the reduction of side effects and drug resistance. Combining drugs is non-trivial due to the high number of possibilities. We applied a feedback system control (FSC) technique with a population-based stochastic search algorithm to navigate through the large parametric space of nine angiostatic drugs at four concentrations to identify optimal low-dose drug combinations. This implied an iterative approach of in vitro testing of endothelial cell viability and algorithm-based analysis. The optimal synergistic drug combination, containing erlotinib, BEZ-235 and RAPTA-C, was reached in a small number of iterations. Final drug combinations showed enhanced endothelial cell specificity and synergistically inhibited proliferation (p < 0.001), but not migration of endothelial cells, and forced enhanced numbers of endothelial cells to undergo apoptosis (p < 0.01). Successful translation of this drug combination was achieved in two preclinical in vivo tumor models. Tumor growth was inhibited synergistically and significantly (p < 0.05 and p < 0.01, respectively) using reduced drug doses as compared to optimal single-drug concentrations. At the applied conditions, single-drug monotherapies had no or negligible activity in these models. We suggest that FSC can be used for rapid identification of effective, reduced dose, multi-drug combinations for the treatment of cancer and other diseases.

Published
2015

30. Discovery of a low order drug-cell response surface for applications in personalized medicine.

Author

Ding, Xianting, Liu, Wenjia, Weiss, Andrea, Li, Yiyang, Wong, Ieong, Griffioen, Arjan W, van den Bergh, Hubert, Xu, Hongquan, Nowak-Sliwinska, Patrycja, and Ho, Chih-Ming

Subjects
Cell Line, Humans, Pharmaceutical Preparations, Drug Therapy, Combination, Regression Analysis, Dose-Response Relationship, Drug, Models, Biological, Molecular Targeted Therapy, Precision Medicine, biological complex system, combinatorial drug, feedback system control, personalized medicine, precision medicine, synergetic and antagonistic interactions, Drug Therapy, Combination, Dose-Response Relationship, Drug, Models, Biological, Individualized Medicine, Biophysics, Engineering, Physical Sciences, Biological Sciences
Abstract

The cell is a complex system involving numerous components, which may often interact in a non-linear dynamic manner. Diseases at the cellular level are thus likely to involve multiple cellular constituents and pathways. As some drugs, or drug combinations, may act synergistically on these multiple pathways, they might be more effective than the respective single target agents. Optimizing a drug mixture for a given disease in a particular patient is particularly challenging due to both the difficulty in the selection of the drug mixture components to start out with, and the all-important doses of these drugs to be applied. For n concentrations of m drugs, in principle, n(m) combinations will have to be tested. As this may lead to a costly and time-consuming investigation for each individual patient, we have developed a Feedback System Control (FSC) technique which can rapidly select the optimal drug-dose combination from the often millions of possible combinations. By testing this FSC technique in a number of experimental systems representing different disease states, we found that the response of cells to multiple drugs is well described by a low order, rather smooth, drug-mixture-input/drug-effect-output multidimensional surface. The main consequences of this are that optimal drug combinations can be found in a surprisingly small number of tests, and that translation from in vitro to in vivo is simplified. This points to the possibility of personalized optimal drug mixtures in the near future. This unexpectedly simple input-output relationship may also lead to a simple solution for handling the issue of human diversity in cancer therapeutics.

Published
2014

31. Age- and gender-matched controls needed for platelet-based biomarker studies

Author

Sabrkhany, Siamack, Kuijpers, Marijke J. E., van Kuijk, Sander M. J., Griffioen, Arjan W., Oude Egbrink, Mirjam G. A., Fysiologie, RS: Carim - B03 Cell biochemistry of thrombosis and haemostasis, Biochemie, MUMC+: HVC Pieken Trombose (9), MUMC+: KIO Kemta (9), RS: CAPHRI - R2 - Creating Value-Based Health Care, Medical oncology laboratory, AII - Cancer immunology, and CCA - Cancer biology and immunology

Subjects
Hematology
Abstract

Not available.

Published
2023

32. Tumor-educated platelet blood tests for Non-Small Cell Lung Cancer detection and management

Author

Antunes-Ferreira, Mafalda, D’Ambrosi, Silvia, Arkani, Mohammad, Post, Edward, in ‘t Veld, Sjors G. J. G., Ramaker, Jip, Zwaan, Kenn, Kucukguzel, Ece Demirel, Wedekind, Laurine E., Griffioen, Arjan W., Oude Egbrink, Mirjam, Kuijpers, Marijke J. E., van den Broek, Daan, Noske, David P., Hartemink, Koen J., Sabrkhany, Siamack, Bahce, Idris, Sol, Nik, Bogaard, Harm-Jan, Koppers-Lalic, Danijela, Best, Myron G., Wurdinger, Thomas, Neurosurgery, Pulmonary medicine, Medical oncology laboratory, AII - Cancer immunology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, ACS - Pulmonary hypertension & thrombosis, CCA - Imaging and biomarkers, and CCA - Cancer immunology

Abstract

Liquid biopsy approaches offer a promising technology for early and minimally invasive cancer detection. Tumor-educated platelets (TEPs) have emerged as a promising liquid biopsy biosource for the detection of various cancer types. In this study, we processed and analyzed the TEPs collected from 466 Non-small Cell Lung Carcinoma (NSCLC) patients and 410 asymptomatic individuals (controls) using the previously established thromboSeq protocol. We developed a novel particle-swarm optimization machine learning algorithm which enabled the selection of an 881 RNA biomarker panel (AUC 0.88). Herein we propose and validate in an independent cohort of samples (n = 558) two approaches for blood samples testing: one with high sensitivity (95% NSCLC detected) and another with high specificity (94% controls detected). Our data explain how TEP-derived spliced RNAs may serve as a biomarker for minimally-invasive clinical blood tests, complement existing imaging tests, and assist the detection and management of lung cancer patients.

Published
2023

46. Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy

Author

Wauters, Annelies C., Scheerstra, Jari F., van Leent, Mandy M. T., Teunissen, Abraham J. P., Priem, Bram, Beldman, Thijs J., Rother, Nils, Duivenvoorden, Raphaël, Prévot, Geoffrey, Munitz, Jazz, Toner, Yohana C., Deckers, Jeroen, van Elsas, Yuri, Mora-Raimundo, Patricia, Chen, Gal, Nauta, Sheqouia A., Verschuur, Anna Vera D., Griffioen, Arjan W., Schrijver, David P., Anbergen, Tom, Li, Yudong, Wu, Hanglong, Mason, Alexander F., van Stevendaal, Marleen H. M. E., Kluza, Ewelina, Post, Richard A. J., Joosten, Leo A. B., Netea, Mihai G., Calcagno, Claudia, Fayad, Zahi A., van der Meel, Roy, Schroeder, Avi, Abdelmohsen, Loai K. E. A., Mulder, Willem J. M., and van Hest, Jan C. M.

Abstract

Regulating innate immunity is an emerging approach to improve cancer immunotherapy. Such regulation requires engaging myeloid cells by delivering immunomodulatory compounds to hematopoietic organs, including the spleen. Here we present a polymersome-based nanocarrier with splenic avidity and propensity for red pulp myeloid cell uptake. We characterized the in vivo behaviour of four chemically identical yet topologically different polymersomes by in vivo positron emission tomography imaging and innovative flow and mass cytometry techniques. Upon intravenous administration, relatively large and spherical polymersomes accumulated rapidly in the spleen and efficiently targeted myeloid cells in the splenic red pulp. When loaded with β-glucan, intravenously administered polymersomes significantly reduced tumour growth in a mouse melanoma model. We initiated our nanotherapeutic’s clinical translation with a biodistribution study in non-human primates, which revealed that the platform’s splenic avidity is preserved across species.

Published
2024
Full Text
View/download PDF

49. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

Author

Cioni, Bianca, Zaalberg, Anniek, van Beijnum, Judy R., Melis, Monique H. M., van Burgsteden, Johan, Muraro, Mauro J., Hooijberg, Erik, Peters, Dennis, Hofland, Ingrid, Lubeck, Yoni, de Jong, Jeroen, Sanders, Joyce, Vivié, Judith, van der Poel, Henk G., de Boer, Jan Paul, Griffioen, Arjan W., Zwart, Wilbert, and Bergman, Andries M.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results